Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 13/20 | 0.56 |
| ▸ | CA1 | P00915 | 11/20 | 0.51 |
| ▸ | CA9 | Q16790 | 8/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27565289 | 0.85 | CA2 (0.49) | CA2CA1CA9GAACA12 | |
| SCHEMBL7145771 | 0.81 | CA2 (0.55) | CA2CA1CA9GAACA12 | |
| SCHEMBL3362967 | 0.81 | CA2 (0.58) | CA2CA1CA9GAACA12 | |
| SCHEMBL283890 | 0.80 | CYP3A4 (0.56) | CA2CA1CA9GAACA12 | |
| SCHEMBL15076431 | 0.80 | CA2 (0.52) | CA2CA1CA9GAACA12 | |
| SCHEMBL15847661 | 0.79 | MAPT (0.61) | CA2CA1CA9CA12SOS1 | |
| SCHEMBL23677295 | 0.79 | TP53 (0.56) | CA2CA1CA9CA12SOS1 | |
| SCHEMBL3361559 | 0.79 | CA2 (0.53) | CA2CA1CA9EPHX2NR1H4 | |
| SCHEMBL13543311 | 0.77 | CA2 (0.51) | CA2CA1CA9EPHX2NR1H4 | |
| SCHEMBL13545187 | 0.77 | CHRNA7 (0.49) | CA2CA1CA9CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1221524-C | Diphenyl ether compounds for therapeutic use | PFIZER LTD (US) | 2005-10-05 | — | — | CN | disclosed |
| EP-1268396-B1 | DIPHENYL ETHER COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2005-07-20 | — | — | EP | disclosed |
| CN-1449380-A | Phenoxybenzylamine derivatives as selective serotonin re-uptake inhibitors | PFIZER LTD (US) | 2003-10-15 | — | — | CN | disclosed |
| US-6610747-B2 | Such as 4-(2,3-dihydro-1-benzothien-5-yloxy)-3-((methylamino) methyl)-benzenesulfonamide for use as serotonin re-uptake inhibitors (SSRIs) in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| CN-1419534-A | Diphenyl ether compounds for therapeutic use | PFIZER LTD (US) | 2003-05-21 | — | — | CN | disclosed |
| US-6448293-B1 | TREATMENT OR PREVENTION OF A DISORDER IN WHICH THE REGULATION OF MONOAMINE TRANSPORTER FUNCTION IS IMPLICATED, SUCH AS PREMATURE EJACULATION. | PFIZER INC. | 2002-09-10 | — | — | US | disclosed |
| US-20020052395-A1 | Diphenyl ether compounds useful in therapy | ANDREWS MARK DAVID (GB) | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052395-A1 | Diphenyl ether compounds useful in therapy | CBR1, OGFR, CBR3 | CA2 1657/4885CA1 3037/4885CA9 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.